293 related articles for article (PubMed ID: 26359463)
21. Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion: subgroup analyses from two randomized trials.
Haller JA; Stalmans P; Benz MS; Gandorfer A; Pakola SJ; Girach A; Kampik A; Jaffe GJ; Toth CA;
Ophthalmology; 2015 Jan; 122(1):117-22. PubMed ID: 25240630
[TBL] [Abstract][Full Text] [Related]
22. Oct-based interpretation of the vitreomacular interface and indications for pharmacologic vitreolysis.
Stalmans P; Duker JS; Kaiser PK; Heier JS; Dugel PU; Gandorfer A; Sebag J; Haller JA
Retina; 2013; 33(10):2003-11. PubMed ID: 23881226
[TBL] [Abstract][Full Text] [Related]
23. Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial.
Dugel PU; Tolentino M; Feiner L; Kozma P; Leroy A
Ophthalmology; 2016 Oct; 123(10):2232-47. PubMed ID: 27499517
[TBL] [Abstract][Full Text] [Related]
24. BASELINE CHARACTERISTICS OF VITREOMACULAR TRACTION PROGRESSING TO FULL-THICKNESS MACULAR OR LAMELLAR HOLES IN THE PHASE III TRIALS OF ENZYMATIC VITREOLYSIS.
Schneider EW; Jaffe GJ
Retina; 2020 Aug; 40(8):1579-1584. PubMed ID: 31415451
[TBL] [Abstract][Full Text] [Related]
25. Visual Function Response to Ocriplasmin for the Treatment of Vitreomacular Traction and Macular Hole: The OASIS Study.
Lescrauwaet B; Duchateau L; Verstraeten T; Jackson TL
Invest Ophthalmol Vis Sci; 2017 Nov; 58(13):5842-5848. PubMed ID: 29141079
[TBL] [Abstract][Full Text] [Related]
26. Early vitreomacular separation with delayed macular hole closure after ocriplasmin treatment.
Liang IC; Wang K; Chien HW; Lin SY
Indian J Ophthalmol; 2016 Mar; 64(3):222-4. PubMed ID: 27146933
[TBL] [Abstract][Full Text] [Related]
27. [Initial Clinical Experiences Using Ocriplasmin for the Treatment of Vitreomacular Traction with or without a Macular Hole].
Lenk J; Matthé E; Ventzke S; Pillunat LE; Sandner D
Klin Monbl Augenheilkd; 2018 Jan; 235(1):73-80. PubMed ID: 28282697
[TBL] [Abstract][Full Text] [Related]
28. From the analysis of pharmacologic vitreolysis to the comprehension of ocriplasmin safety.
Morescalchi F; Gambicorti E; Duse S; Costagliola C; Semeraro F
Expert Opin Drug Saf; 2016 Sep; 15(9):1267-78. PubMed ID: 27388220
[TBL] [Abstract][Full Text] [Related]
29. Baseline Predictors of Vitreomacular Adhesion/Traction Resolution Following an Intravitreal Injection of Ocriplasmin.
Jackson TL; Regillo CD; Girach A; Dugel PU;
Ophthalmic Surg Lasers Imaging Retina; 2016 Aug; 47(8):716-23. PubMed ID: 27548448
[TBL] [Abstract][Full Text] [Related]
30. [Clinical evaluation of ocriplasmin as a vitreolytic agent].
Li L; Du H; Li M; Hui Y
Zhonghua Yan Ke Za Zhi; 2015 Feb; 51(2):155-60. PubMed ID: 25908008
[TBL] [Abstract][Full Text] [Related]
31. Frequency of vitreomacular interface disease in patients presenting to a tertiary care institution.
Xu LT; Punjabi OS; Shao J; Ehlers JP; Srivastava SK; Singh RP; Kaiser PK
Ophthalmic Surg Lasers Imaging Retina; 2014; 45(6):517-20. PubMed ID: 25423630
[TBL] [Abstract][Full Text] [Related]
32. Chronic Serous Macular Detachments and Visual Disturbance Complicating Consecutive Cases of Symptomatic Vitreomacular Adhesion With Macular Hole Treated With Ocriplasmin.
Luttrull JK
Ophthalmic Surg Lasers Imaging Retina; 2015 Oct; 46(9):976-8. PubMed ID: 26469240
[TBL] [Abstract][Full Text] [Related]
33. Safety profile of ocriplasmin for the pharmacologic treatment of symptomatic vitreomacular adhesion/traction.
Kaiser PK; Kampik A; Kuppermann BD; Girach A; Rizzo S; Sergott RC
Retina; 2015 Jun; 35(6):1111-27. PubMed ID: 25635577
[TBL] [Abstract][Full Text] [Related]
34. Treatment of vitreomacular traction with intravitreal ocriplasmin preceded by anterior chamber paracentesis: case reports.
Rizzo S; Bacherini D; Abbruzzese G; Giuntoli M; Virgili G
Eur J Ophthalmol; 2016 Aug; 26(5):e134-7. PubMed ID: 26951534
[TBL] [Abstract][Full Text] [Related]
35. [Ocriplasmin as a treatment option for symptomatic vitreomacular traction with and without macular hole. First clinical experiences].
Maier M; Abraham S; Frank C; Feucht N; Lohmann CP
Ophthalmologe; 2015 Dec; 112(12):990-4. PubMed ID: 26062717
[TBL] [Abstract][Full Text] [Related]
36. Looking at ocriplasmin as a new option in eye disease.
Mitchell MD; Miller DM
Drugs Today (Barc); 2012 Aug; 48(8):519-24. PubMed ID: 22916339
[TBL] [Abstract][Full Text] [Related]
37. Ocriplasmin Treatment Leads to Symptomatic Vitreomacular Adhesion/Vitreomacular Traction Resolution in the Real-World Setting: The Phase IV ORBIT Study.
Khanani AM; Duker JS; Heier JS; Kaiser PK; Joondeph BC; Kozma P; Rosberger DF; MacCumber M; Boyer DS; Pieramici DJ
Ophthalmol Retina; 2019 Jan; 3(1):32-41. PubMed ID: 30935657
[TBL] [Abstract][Full Text] [Related]
38. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes.
Hong J; Deng SX; Xu J
N Engl J Med; 2012 Nov; 367(21):2053; author reply 2054. PubMed ID: 23171110
[No Abstract] [Full Text] [Related]
39. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes.
Rao RC; Dlouhy BJ
N Engl J Med; 2012 Nov; 367(21):2053; author reply 2054. PubMed ID: 23171109
[No Abstract] [Full Text] [Related]
40. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes.
Huang J; Wen D; Wang Q
N Engl J Med; 2012 Nov; 367(21):2052-3; author reply 2054. PubMed ID: 23171108
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
